Make precision oncology evidence more actionable lp

Make precision oncology evidence more actionable

Targeted oncology therapies are transforming cancer care, but generating the real-world evidence needed to support development, access and adoption can be challenging. Novel biomarkers may be slow to enter routine clinical practice, testing approaches can vary by site or country, and low-prevalence biomarkers can make studies difficult to power.

In this IQVIA white paper, learn how a comprehensive RWE approach can help address these barriers. The paper explores how linked biomarker and clinical data, retrospective testing of archival tissue samples and AI-enabled access to imaging and pathology data can support more feasible, efficient and valuable precision oncology studies.

Download the white paper to explore:

Why real-world evidence is increasingly important for targeted oncology therapies
Common challenges in generating RWE for novel and under-tested biomarkers
How linked biomarker and EMR data can support better site selection and study feasibility
How retrospective archival tissue testing can make previously difficult studies possible
How imaging and pathology data can support AI-enabled biomarker discovery and precision oncology strategies

First Name

Last Name

Company

Job Title

Country

State or Province

Numbers

Industry

Function

Role

of Function would

Which type of follow-up would be most helpful?

Paragraph Text

Checkboxes (copy)

You agree Citeline and IQVIA may contact you directly about industry news, products, services and events that may be of interest to you subject to the privacy policies of Citeline and IQVIA.